Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALGS NASDAQ:BDTX NASDAQ:PASG NASDAQ:RUBY NASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALGSAligos Therapeutics$10.44+4.5%$9.92$3.76▼$46.80$61.45M2.77100,856 shs72,809 shsBDTXBlack Diamond Therapeutics$4.11+2.5%$3.29$1.20▼$4.45$228.31M3.071.11 million shs730,514 shsPASGPassage Bio$8.54+5.8%$7.52$5.12▼$26.60$25.65M1.8135,469 shs36,207 shsRUBYRubius Therapeutics$0.06$0.04$0.00▼$0.38$5.16M2.591.15 million shs755,858 shsTSHATaysha Gene Therapies$4.72$3.51$1.05▼$5.51$1.29B0.9911.45 million shs5.06 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALGSAligos Therapeutics0.00%+5.94%+3.31%+15.63%+37.79%BDTXBlack Diamond Therapeutics0.00%-1.96%+22.26%+27.30%+21.15%PASGPassage Bio0.00%-4.72%+12.55%+53.13%-30.37%RUBYRubius Therapeutics0.00%0.00%0.00%0.00%0.00%TSHATaysha Gene Therapies0.00%-3.28%+66.78%+86.56%+129.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALGSAligos Therapeutics$10.44+4.5%$9.92$3.76▼$46.80$61.45M2.77100,856 shs72,809 shsBDTXBlack Diamond Therapeutics$4.11+2.5%$3.29$1.20▼$4.45$228.31M3.071.11 million shs730,514 shsPASGPassage Bio$8.54+5.8%$7.52$5.12▼$26.60$25.65M1.8135,469 shs36,207 shsRUBYRubius Therapeutics$0.06$0.04$0.00▼$0.38$5.16M2.591.15 million shs755,858 shsTSHATaysha Gene Therapies$4.72$3.51$1.05▼$5.51$1.29B0.9911.45 million shs5.06 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALGSAligos Therapeutics0.00%+5.94%+3.31%+15.63%+37.79%BDTXBlack Diamond Therapeutics0.00%-1.96%+22.26%+27.30%+21.15%PASGPassage Bio0.00%-4.72%+12.55%+53.13%-30.37%RUBYRubius Therapeutics0.00%0.00%0.00%0.00%0.00%TSHATaysha Gene Therapies0.00%-3.28%+66.78%+86.56%+129.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALGSAligos Therapeutics 2.00Hold$50.00378.93% UpsideBDTXBlack Diamond Therapeutics 2.57Moderate Buy$9.60133.58% UpsidePASGPassage Bio 2.50Moderate Buy$75.67786.03% UpsideRUBYRubius Therapeutics 0.00N/AN/AN/ATSHATaysha Gene Therapies 2.80Moderate Buy$9.2595.97% UpsideCurrent Analyst Ratings BreakdownLatest BDTX, RUBY, TSHA, PASG, and ALGS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/17/2025TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.0010/17/2025TSHATaysha Gene TherapiesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.0010/15/2025BDTXBlack Diamond TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.0010/10/2025BDTXBlack Diamond TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold10/8/2025ALGSAligos TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025BDTXBlack Diamond TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/8/2025PASGPassage BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025TSHATaysha Gene TherapiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/2/2025TSHATaysha Gene TherapiesRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $12.0010/2/2025TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $10.009/27/2025ALGSAligos TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALGSAligos Therapeutics$3.94M16.30N/AN/A($7.50) per share-1.39BDTXBlack Diamond TherapeuticsN/AN/AN/AN/A$1.47 per shareN/APASGPassage BioN/AN/AN/AN/A$19.84 per shareN/ARUBYRubius TherapeuticsN/AN/AN/AN/A$0.17 per shareN/ATSHATaysha Gene Therapies$8.33M154.58N/AN/A$0.35 per share13.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALGSAligos Therapeutics-$131.21M-$19.79N/AN/AN/A-2,337.24%-22.41%-12.09%11/5/2025 (Estimated)BDTXBlack Diamond Therapeutics-$69.68M$0.2317.87N/AN/AN/A12.70%9.58%11/4/2025 (Estimated)PASGPassage Bio-$64.77M-$18.16N/AN/AN/AN/A-103.87%-59.95%11/12/2025 (Estimated)RUBYRubius Therapeutics-$179.67MN/A0.00∞N/AN/AN/AN/AN/ATSHATaysha Gene Therapies-$89.30M-$0.34N/AN/AN/A-1,144.97%-78.44%-44.82%11/12/2025 (Estimated)Latest BDTX, RUBY, TSHA, PASG, and ALGS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025PASGPassage Bio-$2.64N/AN/AN/AN/AN/A11/12/2025Q3 2025TSHATaysha Gene Therapies-$0.09N/AN/AN/A$1.51 millionN/A11/5/2025Q3 2025ALGSAligos Therapeutics-$2.09N/AN/AN/A$0.50 millionN/A11/4/2025Q3 2025BDTXBlack Diamond Therapeutics-$0.23N/AN/AN/AN/AN/A8/12/2025Q2 2025PASGPassage Bio-$4.00-$2.96+$1.04-$2.96N/AN/A8/12/2025Q2 2025TSHATaysha Gene Therapies-$0.07-$0.09-$0.02-$0.09$1.61 million$1.99 million8/7/2025Q2 2025BDTXBlack Diamond Therapeutics-$0.25-$0.19+$0.06-$0.19N/AN/A8/6/2025Q2 2025ALGSAligos Therapeutics-$2.35-$1.53+$0.82-$1.53$0.43 million$0.97 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALGSAligos TherapeuticsN/AN/AN/AN/AN/ABDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/APASGPassage BioN/AN/AN/AN/AN/ARUBYRubius TherapeuticsN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALGSAligos TherapeuticsN/A6.316.31BDTXBlack Diamond TherapeuticsN/A8.738.73PASGPassage BioN/A3.053.05RUBYRubius TherapeuticsN/AN/AN/ATSHATaysha Gene Therapies0.1712.4812.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALGSAligos Therapeutics60.43%BDTXBlack Diamond Therapeutics95.47%PASGPassage Bio53.48%RUBYRubius TherapeuticsN/ATSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipALGSAligos Therapeutics4.80%BDTXBlack Diamond Therapeutics5.97%PASGPassage Bio4.30%RUBYRubius Therapeutics5.30%TSHATaysha Gene Therapies3.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALGSAligos Therapeutics906.15 million5.86 millionNo DataBDTXBlack Diamond Therapeutics9056.94 million53.54 millionOptionablePASGPassage Bio1303.18 million3.04 millionOptionableRUBYRubius Therapeutics690.48 million85.69 millionNot OptionableTSHATaysha Gene Therapies180272.80 million262.48 millionOptionableBDTX, RUBY, TSHA, PASG, and ALGS HeadlinesRecent News About These CompaniesTaysha Gene Therapies initiated with a Strong Buy at Raymond James5 hours ago | msn.comTaysha Gene Therapies' (TSHA) "Buy" Rating Reiterated at Needham & Company LLCOctober 20 at 2:12 AM | americanbankingnews.comTaysha Gene Therapies' (TSHA) Buy Rating Reiterated at Chardan CapitalOctober 20 at 2:27 AM | americanbankingnews.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Down 11.9% - Here's What HappenedOctober 18 at 12:45 PM | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Earns "Buy" Rating from Needham & Company LLCOctober 18 at 8:29 AM | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Earns "Buy" Rating from Chardan CapitalOctober 18 at 8:18 AM | marketbeat.comHow Regaining Full Rights to Rett Syndrome Gene Therapy Has Changed Taysha (TSHA)’s Investment StoryOctober 17 at 11:44 PM | finance.yahoo.comTaysha Gene Therapies, Inc.: Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett SyndromeOctober 17 at 6:43 PM | finanznachrichten.deAstellas walks away from gene therapy pact with Taysha before pivotal trial launchOctober 17 at 6:43 PM | fiercebiotech.comFNeedham Reiterates Taysha Gene Therapies (TSHA) Buy RecommendationOctober 17 at 6:43 PM | msn.comTaysha Gene Therapies Regains Full Rights to Rett Syndrome ProgramOctober 16, 2025 | marketwatch.comTaysha Gene Therapies regains full rights to TSHA-102 programOctober 16, 2025 | msn.comTaysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett SyndromeOctober 16, 2025 | globenewswire.comTaysha Gene Therapies (NASDAQ:TSHA) Hits New 52-Week High - Should You Buy?October 15, 2025 | marketbeat.comTruist Financial Remains a Buy on Taysha Gene Therapies (TSHA)October 12, 2025 | theglobeandmail.comTaysha Gene Therapies price target raised to $9 from $8 at BofAOctober 10, 2025 | msn.comWeiss Ratings Reiterates Sell (D-) Rating for Taysha Gene Therapies (NASDAQ:TSHA)October 9, 2025 | marketbeat.comTaysha Gene Therapies presents new supplemental data analysis from REVEAL studyOctober 9, 2025 | msn.comTaysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual MeetingOctober 9, 2025 | globenewswire.comTaysha Gene Therapies (NASDAQ:TSHA) Trading Down 4.9% - Time to Sell?October 6, 2025 | marketbeat.comTaysha Gene Therapies: Breakthrough Rett Program With BLA Acceleration PotentialOctober 6, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBDTX, RUBY, TSHA, PASG, and ALGS Company DescriptionsAligos Therapeutics NASDAQ:ALGS$10.44 +0.45 (+4.50%) Closing price 04:00 PM EasternExtended Trading$10.20 -0.24 (-2.35%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Black Diamond Therapeutics NASDAQ:BDTX$4.11 +0.10 (+2.49%) Closing price 04:00 PM EasternExtended Trading$4.10 -0.01 (-0.24%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Passage Bio NASDAQ:PASG$8.54 +0.47 (+5.82%) Closing price 03:59 PM EasternExtended Trading$8.69 +0.15 (+1.71%) As of 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Rubius Therapeutics NASDAQ:RUBYRubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.Taysha Gene Therapies NASDAQ:TSHA$4.72 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$4.89 +0.18 (+3.71%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner JPMorgan Crushes Q3; But Is the Steady Eddy Stock Hitting A Wall? Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
